glp-1 weight loss drugs news today U.S. Obesity Rate Drops as Use of Surges | National Chart: 1 in 8 Americans
Description
The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).
Sources for Figure 218
Learn about the benefits and practical steps for transitioning patients from GLP-1 RAs to dual GLP-1/GIP receptor agonists, such as tirzepatide, to improve glycemic control in adults with type 2 diabetes.
These are serious prescription medicines not quick-fix weight loss solutions
Compare early results with Wegovy and Mounjaro.
This natural GLP-1 support supplement is ideal for individuals seeking
